Subsidiary Board Approves Amalgamation of Actis Generics with RPG Active Pharma
Subsidiary RPG Active Pharma's Board approved a Scheme of Amalgamation of its wholly owned subsidiary Actis Generics into itself.
By ScoutQuest · · 2 min read
- Actis Generics Net Worth
- INR 34.60 Crore
- Actis Generics Revenue FY 2025-26
- INR 45.96 Crore
- RPGAP Net Worth
- INR 34.75 Crore
- Consideration
- No shares issued; wholly owned subsidiary
- Approval Status
- Subject to NCLT nod
What was announced
RPG Life Sciences informed the exchanges that its subsidiary, RPG Active Pharma Limited (RPGAP), received Board approval for a Scheme of Amalgamation of Actis Generics Private Limited with RPGAP, under Sections 230 to 232 of the Companies Act, 2013.
Actis Generics is already a wholly owned subsidiary of RPGAP, so this is an internal group restructuring.
The numbers
- RPGAP (Transferee) net worth: INR 34.75 Crore as on March 31, 2026. It was incorporated on 24th December 2025 and had no revenue from operations in FY26.
- Actis Generics (Transferor) net worth: INR 34.60 Crore as on March 31, 2026.
- Actis Generics revenue from operations: INR 45.96 Crore during financial year 2025-26.
Businesses involved
- Actis Generics manufactures pharmaceutical, medical chemicals and botanical products.
- RPGAP manufactures and markets active pharmaceutical ingredients.
Rationale stated
The company cites streamlining of the corporate structure, consolidation of assets and liabilities, more efficient use of capital, simpler compliance, better management oversight, cost savings through legal entity rationalisation, and a stronger balance sheet and net worth for the transferee, which it says could help with lender terms.
Consideration and shareholding
Because the transferor is a wholly owned subsidiary, no shares will be issued as consideration. All shares of Actis Generics held by RPGAP and its nominees will stand cancelled once the Scheme becomes effective. There will be no change in the shareholding pattern of RPG Life Sciences.
Both entities are related parties to each other. The update notes that per the MCA General Circular No. 30/2014, transactions arising out of amalgamations under the Companies Act do not attract Section 188 requirements.
What happens next
The Scheme is subject to approvals from the jurisdictional bench of the National Company Law Tribunal, the shareholders of RPG Active and Actis Generics, and other authorities as required.
How to read it
This is a housekeeping-style consolidation within the group rather than an external acquisition. Since no shares are issued and the listed entity's shareholding stays unchanged, the direct impact on shareholders is structural, with the stated benefits being efficiency and simplification.
Also from RPG Life Sciences
RPG Life Sciences to hold Q2 FY27 results earnings call on October 30, 2026 at 5:00 PM IST
23 Oct 2026
Board Meeting on October 29, 2026 to Approve Q2 and H1 Results
23 Oct 2026
RPG Life Sciences Ltd shareholder buys 0.23% stake, holding rises to 7.04%
28 Sep 2026
More numbers
- RPGAP net worth as on March 31, 2026INR 34.75 Crore
- Actis Generics net worth as on March 31, 2026INR 34.60 Crore
- Actis Generics revenue from operations FY 2025-26INR 45.96 Crore
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.